Hjem › Neuroblastom › Massachusetts
Kliniske studier for Neuroblastom i Massachusetts
13 studier for Neuroblastom søker deltakere på steder i Massachusetts.
Byer i Massachusetts
Offisiell studietekst (engelsk)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 3
Opp til 30 år · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Rekrutterer
Alle aldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
RekruttererFase 1
9 Months – 30 Years · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 3
365 Days – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 2 til 21 · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 1 til 30 · Alle kjønn · Oppdatert 22. jul. 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
RekruttererFase 2
Alder 1 til 31 · Alle kjønn · Oppdatert 20. jul. 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 1 til 30 · Alle kjønn · Oppdatert 14. jul. 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
RekruttererObservasjonsstudie
31 Days – 99 Years · Alle kjønn · Oppdatert 23. mar. 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Rekrutterer
Opp til 17 år · Alle kjønn · Oppdatert 10. feb. 2026 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
12 Months – 29 Years · Alle kjønn · Oppdatert 26. des. 2025 · NCT06803875Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.